secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001558370-23-008080
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium reports record Q1 revenue $144.8M, adjusted EPS $1.32, reaffirms FY23 guide
--------------------------------------------------------------------------------

- Record product revenue net of $144.8M, up 73% YoY from $83.8M.
- Non-GAAP adjusted net income $51.7M with adjusted EPS $1.32 vs $0.71 YoY.
- Adjusted EBITDA $87.6M, up 101% YoY from $43.5M.
- Cash balance $269.5M; completed $241.5M convertible note offering due 2029.
- Reaffirmed FY23 product revenue $565-580M and adjusted EBITDA $355-370M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000155837023008080/0001558370-23-008080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000155837023008080/coll-20230504x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-008080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer